Microdose therapy

• US 6,610,652 B2
• Filed: 03/08/2002
• Issued: 08/26/2003
• Est. Priority Date: 06/23/1997
• Status: Expired due to Fees

• Current Assignee: Queen's University At Kingston
• Original Assignee: Queen's University At Kingston
• Inventors: Adams, Michael A., Heaton, Jeremy P. W., Banting, James D.
• Primary Examiner(s): HENLEY III, RAYMOND J
• Application Number:
  US10/095,654
• Publication Number:
  US 20020091088A1
• Time in Patent Office: 536 Days
• Field of Search: 514/2, 514/192, 514/231.2, 514/470, 514/565, 514/668
• US Class Current: 424/718
• CPC Class Codes: A61K 31/04 Nitro compounds
• CPC Class Codes: A61K 31/16 Amides, e.g. hydroxamic acids
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/21 Esters, e.g. nitroglycerine, selenocyanates
• CPC Class Codes: A61K 31/295 Iron group metal compounds
• CPC Class Codes: A61K 31/34 having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
• CPC Class Codes: A61K 31/5377 not condensed and containing further heterocyclic rings, e.g. timolol
• CPC Class Codes: A61K 38/063 Glutathione
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/02 for disorders of the vagina
• CPC Class Codes: A61P 15/10 for impotence
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Methods for treating vascular conditions associated with localized imbalance in vascular tone, which are hypothesized to be largely due to elevated endothelin (ET) are provided. The methods involve administration of nitric oxide (NO), agents which are able to provide NO, such as NO donors, agents which activate guanyl cyclase, such as YC-1, or agents which prolong the actions of endogenous NO or cyclic guanosine monophosphate (cGMP; a 2nd messenger molecule), such as phosphodiesterase (PDE) inhibitors. According to the invention, such agents are administered in minimal doses or microdoses by any route known in the art, so as to provide dosages which are about one half to about one twentieth (½ to {fraction (1/20)}) of those known to induce vasodilation in “normal” circulations. The low doses of these agents effectively alleviate vascular conditions associated with a reduction in NO production or an attenuation of NO effect, by restoring balance in vascular tone while exerting almost no systemic effect in normal vasculature.

Claims

1. A method for treating a urogenital disorder in a female subject, said method comprising:

administering to said female subject an agent that enhances NO while maintaining normal systemic vascular tone, to treat said urogenital disorder in said female subject.

2. The method for treating a urogenital disorder of claim 1, wherein said urogenital disorder is selected from the group consisting of decreased vaginal lubrication, decreased vaginal engorgement, pain during intercourse, dyspareunia, urogenital infections, effects on urogenitalia due to post-menopause or diabetes, vascular disease, estrogen depletion conditions, sexual dysfunction, and idiosyncratic vaginal dryness.

3. The method for treating a urogenital disorder of claim 2, wherein said urogenital disorder is selected from the group consisting of decreased vaginal engorgement, pain during intercourse and dyspareunia.

4. The method for treating a urogenital disorder of claim 3, wherein said urogenital disorder is dyspareunia.

5. The method for treating a urogenital disorder of claim 1, wherein said administration of said agent is selected from the group consisting of oral, sublingual, buccal, intravenous, transdermal, vaginal, rectal, by inhalation, enteral, and parental.

6. The method for treating a urogenital disorder of claim 1, wherein administration of said agent is at concentration that is about ½

to about {fraction (1/20)} of a concentration of said agent required to induce vasodilation in a healthy vasculature.

7. The method for treating a urogenital disorder of claim 6, wherein administration of said agent is at concentration that is about ¼

to about {fraction (1/20)} of a concentration of said agent required to induce vasodilation in healthy vasculature.

8. The method for treating a urogenital disorder of claim 7, wherein administration of said agent is at concentration that is about ⅛

to about {fraction (1/16)} of a concentration of said agent required to induce vasodilation in healthy vasculature.

9. The method for treating a urogenital disorder of claim 1, wherein said agent which enhances NO is GTN, and said level of administration is a plasma concentration below about 250 pg/ml of GTN.

10. The method for treating a urogenital disorder of claim 1, wherein said agent is selected from the group consisting of NO, CO. NO donors, CO donors, activators of guanylyl cyclase, PDE inhibitors, and substances which produce an effect equivalent to that of NO.

11. The method for treating a urogenital disorder of claim 10, wherein said agent is a PDE inhibitor.

12. The method for treating a urogenital disorder of claim 10, wherein said NO donor is selected from the group consisting of glyceryl trinitrate, isosorbide 5-mononitrate, isosorbide dinitrate, pentaerythritol tetranitrate, erythrityl tetranitrate, sodium nitroprusside, 3-morpholinosydnonimine molsidomine, S-nitroso-N-acetylpenicillamine, S-nitrosoglutathione, and N-hydroxy-L-arginine.

13. The method for treating a urogenital disorder of claim 12, wherein said NO donor is glyceryl trinitrate (GTN).

14. A method for improving blood flow to the vagina, said method comprising:

administering to a female subject an agent that enhances NO while maintaining normal systemic vascular tone, to improve blood flow to the vagina.

15. A method for treating dyspareunia in a female subject, said method comprising:

administering to said female subject an agent that enhances NO while maintaining normal systemic vascular tone, to treat dyspareunia in said female subject.

16. A method for treating a urogenital disorder in a female subject, said method comprising:

topically administering to said female subject an agent that enhances NO while maintaining normal systemic vascular tone, to treat said urogenital disorder in said female subject.

17. A method for restoring NO/ET balance in a female subject, said method comprising:

administering to said female subject an agent that enhances NO while maintaining normal systemic vascular tone, to restore NO/ET balance in said female subject.

18. A method for treating an estrogen depletion condition in a female subject, said method comprising:

administering to said female subject an agent that enhances NO while maintaining normal systemic vascular tone, to treat said estrogen depletion condition in said female subject.

19. A method for improving vaginal blood flow in a female subject, said method comprising:

administering to said female subject an agent that enhances NO while maintaining normal systemic vascular tone, to improve vaginal blood flow in said female subject.

20. A method for improving vaginal lubrication in a female subject, said method comprising:

administering to said female subject an agent that enhances NO while maintaining normal systemic vascular tone, to improve vaginal lubrication in said female subject.